Comparative Pharmacology
Head-to-head clinical analysis: AVANAFIL versus CHEWTADZY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANAFIL versus CHEWTADZY.
AVANAFIL vs CHEWTADZY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Unoprostone
"Avanafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateAvanafil + Hydrochlorothiazide
"Avanafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (CrCl <30 mL/min)
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor